Form 4: Oruka Therapeutics President Sells Shares
Insider Transaction (Form 4)
Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics, Inc., sold 10,019 shares of common stock on September 11, 2026.
Summary
- Option exercise/conversion: acquired 8,000 Common Stock at $12.50 ($100,000) on September 11, 2026; holds 23,312 after (Direct).
- Option exercise/conversion: acquired 1,459 Common Stock at $34.39 ($50,175) on September 11, 2026; holds 24,771 after (Direct).
- Open-market sale: disposed of 3,000 Common Stock at $91.11 ($273,322) on September 11, 2026; holds 21,771 after (Direct).
- Open-market sale: disposed of 4,051 Common Stock at $92.41 ($374,367) on September 11, 2026; holds 17,720 after (Direct).
- Open-market sale: disposed of 2,208 Common Stock at $93.26 ($205,921) on September 11, 2026; holds 15,512 after (Direct).
- Open-market sale: disposed of 200 Common Stock at $94.02 ($18,803) on September 11, 2026; holds 15,312 after (Direct).
- Open-market sale: disposed of 560 Common Stock at $95.71 ($53,598) on September 15, 2026; holds 14,752 after (Direct).
- Option exercise/conversion: disposed of 8,000 Employee Stock Option (right to buy) on September 11, 2026; holds 84,917 after (Direct).
- Option exercise/conversion: disposed of 1,459 Employee Stock Option (right to buy) on September 11, 2026; holds 58,333 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $926,010 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Arjun Agarwal — Officer (Senior Vice President, Finance)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-11 | Option exercise/conversion | Common Stock | 8,000 | $13 | $100.0K | 23,312 |
| 2026-09-11 | Option exercise/conversion | Common Stock | 1,459 | $34 | $50.2K | 24,771 |
| 2026-09-11 | Open-market sale | Common Stock | 3,000 | $91 | $273.3K | 21,771 |
| 2026-09-11 | Open-market sale | Common Stock | 4,051 | $92 | $374.4K | 17,720 |
| 2026-09-11 | Open-market sale | Common Stock | 2,208 | $93 | $205.9K | 15,512 |
| 2026-09-11 | Open-market sale | Common Stock | 200 | $94 | $18.8K | 15,312 |
| 2026-09-15 | Open-market sale | Common Stock | 560 | $96 | $53.6K | 14,752 |
| 2026-09-11 | Option exercise/conversion | Employee Stock Option (right to buy) | 8,000 | — | — | 84,917 |
| 2026-09-11 | Option exercise/conversion | Employee Stock Option (right to buy) | 1,459 | — | — | 58,333 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-11 | Option exercise/conversion (8,000 shares) |
| 2026-09-11 | Option exercise/conversion (1,459 shares) |
| 2026-09-11 | Open-market sale (3,000 shares) |
| 2026-09-11 | Open-market sale (4,051 shares) |
| 2026-09-11 | Open-market sale (2,208 shares) |
| 2026-09-11 | Open-market sale (200 shares) |
| 2026-09-15 | Open-market sale (560 shares) |
| 2026-09-11 | Option exercise/conversion (8,000 shares) |
| 2026-09-11 | Option exercise/conversion (1,459 shares) |
Keywords
insider transaction, Form 4, ORKA, Oruka Therapeutics, Inc., bearish, Arjun Agarwal
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.